Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL320565 | 1.00 | TRPA1 (0.31) | TRPA1 | |
| SCHEMBL183299 | 1.00 | TRPA1 (0.31) | TRPA1 | |
| SCHEMBL8579729 | 1.00 | TRPA1 (0.31) | TRPA1 | |
| SCHEMBL183105 | 1.00 | — | — | |
| SCHEMBL168854 | 1.00 | TRPA1 (0.31) | TRPA1 | |
| SCHEMBL8734069 | 1.00 | TRPA1 (0.31) | TRPA1 | |
| SCHEMBL166888 | 1.00 | — | — | |
| SCHEMBL168949 | 0.97 | — | — | |
| SCHEMBL165972 | 0.87 | — | — | |
| SCHEMBL7114578 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181607-A1 | THIOSACCHARIDES FOR USE IN TREATING CORONAVIRUS INFECTION | The University of the Regents of California (US) | 2023-06-15 | — | — | US | disclosed |
| EP-4149481-A1 | THIOSACCHARIDES FOR USE IN TREATING CORONAVIRUS INFECTION | The Regents of the University of California (US) | 2023-03-22 | — | — | EP | disclosed |
| CN-115177626-A | Thiosyl mucolytic agents and uses and compositions thereof | 加利福尼亚大学董事会 | 2022-10-14 | — | — | CN | disclosed |
| CN-105228605-B | Thiosyl mucolytic agents | 加利福尼亚大学董事会 | 2022-08-12 | — | — | CN | disclosed |
| WO-2021231397-A1 | THIOSACCHARIDES FOR USE IN TREATING CORONAVIRUS INFECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-18 | — | — | WO | disclosed |
| EP-3891818-A1 | SELF-ASSEMBLED MONOLAYER FOR ELECTRODE MODIFICATION AND DEVICE COMPRISING SUCH SELF-ASSEMBLED MONOLAYER | Merck Patent GmbH (DE) | 2021-10-13 | — | — | EP | disclosed |
| CN-108024913-B | Curable composition, curable composition for dentistry, and organic-inorganic composite particle for dentistry | 德山齿科株式会社 | 2021-08-10 | — | — | CN | disclosed |
| EP-3851109-A1 | THIOSACCHARIDE MUCOLYTIC AGENTS | The Regents of the University of California (US) | 2021-07-21 | — | — | EP | disclosed |
| US-11021506-B2 | Thiosaccharide mucolytic agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | disclosed |
| EP-2968215-B1 | THIOSACCHARIDE MUCOLYTIC AGENTS | UNIV CALIFORNIA (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20030216412-A1 | Methanocarba cycloakyl nucleoside analogues | HEALTH AND HUMAN SERVICES, GOVERNMENT OF THE UNITED STATES OF AMERICA, THE, REPRESENTED BY THE SECRETARY, DEPARTMENT OF | 2003-11-20 | — | — | US | disclosed |
| US-20030027785-A1 | Joint lubrication with P2Y purinergic receptor agonists | INSPIRE PHARMACEUTICALS, INC. | 2003-02-06 | — | — | US | disclosed |
| WO-2003000056-A1 | JOINT LUBRICATION WITH P2Y PURINERGIC RECEPTOR AGONISTS | INSPIRE PHARMACEUTICALS, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2002086000-A1 | UNSATURATED COMPOUNDS CONTAINING CARBAMATE TERMINAL GROUPS OR UREA TERMINAL GROUPS | BASF AKTIENGESELLSCHAFT (DE) | 2002-10-31 | — | — | WO | disclosed |
| EP-1252160-A1 | METHANOCARBA CYCLOALKYL NUCLEOSIDE ANALOGUES | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001051490-A1 | METHANOCARBA CYCLOALKYL NUCLEOSIDE ANALOGUES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-07-19 | — | — | WO | disclosed |
| EP-0412933-B1 | Coating compositions | CIBA GEIGY AG (CH) | 1994-09-14 | — | — | EP | disclosed |
| US-5183842-A | Mixture of ketoacid and amine with film-forming binder, curing | CIBA-GEIGY CORPORATION (US) | 1993-02-02 | — | — | US | disclosed |
| US-5128396-A | Corrosion inhibiting primers on metallic substrates | CIBA-GEIGY CORPORATION (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0412933-A1 | Coating compositions | CIBA-GEIGY AG (CH) | 1991-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216412-A1 | Methanocarba cycloakyl nucleoside analogues | P2RY1, ADORA1, ADORA2A | TRPA1 130/4885 |
| US-11021506-B2 | Thiosaccharide mucolytic agents | MUC1, TREH, FUT6 | TRPA1 1259/4885 |
| US-20030027785-A1 | Joint lubrication with P2Y purinergic receptor agonists | P2RY1, P2RY2, P2RY6 | TRPA1 643/4885 |
| US-20230181607-A1 | THIOSACCHARIDES FOR USE IN TREATING CORONAVIRUS INFECTION | TMPRSS4, ACE, ACE2 | TRPA1 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.